These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33323403)

  • 21. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
    Parkinson CA; Gale D; Piskorz AM; Biggs H; Hodgkin C; Addley H; Freeman S; Moyle P; Sala E; Sayal K; Hosking K; Gounaris I; Jimenez-Linan M; Earl HM; Qian W; Rosenfeld N; Brenton JD
    PLoS Med; 2016 Dec; 13(12):e1002198. PubMed ID: 27997533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic and prognostic significance of serum CD26 level in Asian women with high-grade serous ovarian carcinoma.
    Shao S; Wang C; Tian J; Zhang H; Wang S; Du Y
    Future Oncol; 2019 Jun; 15(16):1863-1871. PubMed ID: 31140312
    [No Abstract]   [Full Text] [Related]  

  • 23. Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
    Garsed DW; Alsop K; Fereday S; Emmanuel C; Kennedy CJ; Etemadmoghadam D; Gao B; Gebski V; Garès V; Christie EL; Wouters MCA; Milne K; George J; Patch AM; Li J; Arnau GM; Semple T; Gadipally SR; Chiew YE; Hendley J; Mikeska T; Zapparoli GV; Amarasinghe K; Grimmond SM; Pearson JV; Waddell N; Hung J; Stewart CJR; Sharma R; Allan PE; Rambau PF; McNally O; Mileshkin L; Hamilton A; Ananda S; Grossi M; Cohen PA; Leung YC; Rome RM; Beale P; Blomfield P; Friedlander M; Brand A; Dobrovic A; Köbel M; Harnett P; Nelson BH; Bowtell DDL; deFazio A;
    Clin Cancer Res; 2018 Feb; 24(3):569-580. PubMed ID: 29061645
    [No Abstract]   [Full Text] [Related]  

  • 24. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.
    Jamieson A; Sobral de Barros J; Cochrane DR; Douglas JM; Shankar S; Lynch BJ; Leung S; Martin S; Senz J; Lum A; Drew Y; Gilks CB; Huntsman DG; McAlpine JN
    Clin Cancer Res; 2024 Jun; 30(11):2461-2474. PubMed ID: 38536067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tensor GSVD of patient- and platform-matched tumor and normal DNA copy-number profiles uncovers chromosome arm-wide patterns of tumor-exclusive platform-consistent alterations encoding for cell transformation and predicting ovarian cancer survival.
    Sankaranarayanan P; Schomay TE; Aiello KA; Alter O
    PLoS One; 2015; 10(4):e0121396. PubMed ID: 25875127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Creation and validation of models to predict response to primary treatment in serous ovarian cancer.
    Gonzalez Bosquet J; Devor EJ; Newtson AM; Smith BJ; Bender DP; Goodheart MJ; McDonald ME; Braun TA; Thiel KW; Leslie KK
    Sci Rep; 2021 Mar; 11(1):5957. PubMed ID: 33727600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High levels of genomic aberrations in serous ovarian cancers are associated with better survival.
    Baumbusch LO; Helland Å; Wang Y; Liestøl K; Schaner ME; Holm R; Etemadmoghadam D; Alsop K; Brown P; ; Mitchell G; Fereday S; DeFazio A; Bowtell DD; Kristensen GB; Lingjærde OC; Børresen-Dale AL
    PLoS One; 2013; 8(1):e54356. PubMed ID: 23372714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
    Smith P; Bradley T; Gavarró LM; Goranova T; Ennis DP; Mirza HB; De Silva D; Piskorz AM; Sauer CM; Al-Khalidi S; Funingana IG; Reinius MAV; Giannone G; Lewsley LA; Stobo J; McQueen J; Bryson G; Eldridge M; ; Macintyre G; Markowetz F; Brenton JD; McNeish IA
    Nat Commun; 2023 Jul; 14(1):4387. PubMed ID: 37474499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
    Yoshida K; Yokoi A; Matsuzaki J; Kato T; Ochiya T; Kajiyama H; Yamamoto Y
    Cancer Sci; 2021 Dec; 112(12):4977-4986. PubMed ID: 34618992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis.
    Kuroda T; Hirohashi Y; Torigoe T; Yasuda K; Takahashi A; Asanuma H; Morita R; Mariya T; Asano T; Mizuuchi M; Saito T; Sato N
    PLoS One; 2013; 8(6):e65158. PubMed ID: 23762304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
    S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.
    Pradjatmo H; Pradjatmo H
    Asian Pac J Cancer Prev; 2016; 17(4):1881-6. PubMed ID: 27221870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas.
    Lin S; Wang C; Zarei S; Bell DA; Kerr SE; Runger GC; Kocher JA
    BMC Genomics; 2018 Nov; 19(1):841. PubMed ID: 30482155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients.
    Van Roy N; Van Der Linden M; Menten B; Dheedene A; Vandeputte C; Van Dorpe J; Laureys G; Renard M; Sante T; Lammens T; De Wilde B; Speleman F; De Preter K
    Clin Cancer Res; 2017 Oct; 23(20):6305-6314. PubMed ID: 28710315
    [No Abstract]   [Full Text] [Related]  

  • 39. Refined characterization of circulating tumor DNA through biological feature integration.
    Markus H; Chandrananda D; Moore E; Mouliere F; Morris J; Brenton JD; Smith CG; Rosenfeld N
    Sci Rep; 2022 Feb; 12(1):1928. PubMed ID: 35121756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.